Inserm, with the support of the REACTing network, Public Health France, the country’s university hospitals, and the French College of Teachers in General Practice, is launching COVIREIVAC. This platform for the clinical evaluation of COVID-19 vaccine candidates will make it possible to test them rigorously and obtain robust data on their safety and ability to induce an immune response (immunogenicity).
Les deux bras testant la combinaison lopinavir/ritonavir avec ou sans interféron bêta sont arrêtés dans les essais cliniques Solidarity et Discovery. Compte tenu de la nature adaptative des deux essais, une réflexion est en cours sur l'évolution du protocole. Des publications dans des journaux internationaux à comité de lecture sont en préparation concernant tant l'évaluation de l'hydroxychloroquine que du lopinavir/ritonavir.
Launched in 2019, the primary objective of the Health Environment Research Agenda for Europe (HERA) is to provide the European Commission with an environment, climate, and health research agenda for 2020-2030.
Les inclusions dans le groupe hydroxychloroquine de l'essai Discovery sont suspendues depuis dimanche 24 mai.
First identified in the central Chinese city of Wuhan in December 2019, the novel SARS-CoV-2 coronavirus has rapidly spread across the world, leading to the most serious pandemic in recent history.
Inria, ANSSI, Capgemini, Dassault Systèmes, Inserm, Lunabee Studio, Orange, Santé Publique France and Withings create the StopCovid project team in order to structure and strengthen their contribution to the government project to set up a mobile contact tracing application (StopCovid). The purpose of this project is to provide the French health authorities with a complementary digital tool to help manage the sanitary emergency against Covid-19.
Furthering scientific knowledge knows no frontiers. Therefore, Inserm would like to reaffirm that the countries of Africa are – more than ever – key scientific partners
The CNRS and Inserm, in association with the CPU, INED, INRAE and IRD, under the umbrella of ATHENA and AVIESAN1, are joining forces to raise key scientific questions on health and environmental crises and combine the initiatives of the humanities, social sciences and public health research communities arising from the current COVID-19 crisis.
At a time when the Sars-CoV-2 epidemic is continuing to spread, France’s Alliance for Life Sciences and Health (Aviesan) is mobilizing to accelerate research into the virus and COVID-19 disease through REACTing – a consortium coordinated by Inserm. The Scientific Advisory Board of REACTing has selected 20 scientific initiatives covering diverse fields, from mathematical modelling to disease prevention and treatment.
Inserm has published a new Collective Expert Review, this time looking at developmental coordination disorder (DCD) – otherwise known as dyspraxia.
